[
  {
    "ts": null,
    "headline": "Labcorp Appoints Victor Bulto to Board of Directors",
    "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.",
    "url": "https://finnhub.io/api/news?id=7f0ee9790870f9fef6015799c00ab500b8135900c33b7d19be09879b3139f9be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763991000,
      "headline": "Labcorp Appoints Victor Bulto to Board of Directors",
      "id": 137589376,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.",
      "url": "https://finnhub.io/api/news?id=7f0ee9790870f9fef6015799c00ab500b8135900c33b7d19be09879b3139f9be"
    }
  },
  {
    "ts": null,
    "headline": "Labcorp (LH): Evaluating Valuation After Breakthroughs in Cancer Diagnostics and AI-Powered Pathology",
    "summary": "Labcorp Holdings (LH) is drawing attention after its Plasma Detect assay was featured in two respected medical journals. The company’s digital pathology joint initiative with Lunit also made headlines at recent oncology conferences. See our latest analysis for Labcorp Holdings. Momentum has been building for Labcorp Holdings over 2025, with investor optimism fueled by advances in diagnostics and AI partnerships. The stock’s strong 1-year total shareholder return of 12.1% reflects both robust...",
    "url": "https://finnhub.io/api/news?id=97acee95065f38b5cb7c2da1eec25dd934b3bcdee7914af1c25fd6f700e3990b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763953942,
      "headline": "Labcorp (LH): Evaluating Valuation After Breakthroughs in Cancer Diagnostics and AI-Powered Pathology",
      "id": 137587045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp Holdings (LH) is drawing attention after its Plasma Detect assay was featured in two respected medical journals. The company’s digital pathology joint initiative with Lunit also made headlines at recent oncology conferences. See our latest analysis for Labcorp Holdings. Momentum has been building for Labcorp Holdings over 2025, with investor optimism fueled by advances in diagnostics and AI partnerships. The stock’s strong 1-year total shareholder return of 12.1% reflects both robust...",
      "url": "https://finnhub.io/api/news?id=97acee95065f38b5cb7c2da1eec25dd934b3bcdee7914af1c25fd6f700e3990b"
    }
  }
]